Learning Objectives; 

  1. Identify when and why octreotide is used in the management of malignant bowel obstructions
  2. Evaluate the benefit of using octreotide to increase symptom-free days
  3. Apply the study findings to our patient population at UCM
  4. To discuss challenges, barriers, and opportunities for deprescribing
  5. To examine strengths and weaknesses of OPTIMIZE trial
Session date: 
09/29/2022 - 8:00am to 9:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Kelsey Dullinger, DO; Laura Kahn, MD, MPH